Keyword: Skyrizi

Despite multiple drugs working through inhibiting inflammatory interleukins, AbbVie's Skyrizi is still carving out a meaningful share.

After years of laborious drug R&D finally yield an approval, biopharma companies hope for a continuous and abundant flow of revenue to make the investment worthwhile. And it all starts with a successful launch. Here are the top 10 recent rollouts that have fulfilled those very hopes, at least so far.

AbbVie hit $33.27 billion in net revenue in 2019 on the back of mostly stable sales for Humira and boosts from blood cancer meds Imbruvica and Venclexta.